Clinical trialRSS2 days ago
Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy
A company called Biovie has finished enrolling patients in a study testing a new oral medication called bezisterim for early-stage Parkinson's disease. The medication is being tested as a standalone treatment that patients could take by mouth. The researchers will now analyze all the data collected, with results expected later this year.
WHY IT MATTERSIf bezisterim proves effective in this Phase 2 trial, it could offer Parkinson's patients a new oral treatment option that works alone without requiring combination with other medications.